Trofinetide
Peptide
Evidence outlook
Approved: Rett Syndrome
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also approved (2)
- Treatment of neurobehavioural symptoms of Rett syndrome in patients aged 5 years and older (brand DAYBU)
- Treatment of Rett syndrome in adult and pediatric patients two years of age and older
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
LAVENDER NCT04181723 · Rett Syndrome This was a randomized, quadruple-blind, placebo-controlled trial of 187 participants. Both primary clinical endpoints were statistically significant in favor of trofinetide, with greater improvement in the RSBQ total score and CGI-I score than with placebo. Registry: NCT04181723 | 3 | Rett Syndrome Behaviour Questionnaire (RSBQ) Total Score - Change From Baseline to Week 12 (Baseline and Week 12); Clinical Global Impression-Improvement (CGI-I) Score at Week 12 (12 Weeks Treatment Duration) 2021-10-28 | Completed. Key figures are not recorded here; the rationale explains the result. | Reliable signal | link ↗ |
View 1 more trial
LILAC NCT04279314 · Rett Syndrome This was a confirmed open-label extension of Study ACP-2566-003, with 154 participants continuing trofinetide in a single treatment group and no randomization, blinding, or comparator. Its primary outcomes were safety measures rather than comparative clinical efficacy endpoints, so the findings provide useful long-term safety information but limited evidence of trofinetide’s treatment effect. Registry: NCT04279314 | 3 | Percentage of Subjects With Treatment-emergent Adverse Events (TEAEs), Percentage of Subjects With Serious Adverse Events (SAEs), and Percentage of Subjects With Withdrawals Due to AEs (40 Weeks Treatment Duration); Subjects (N, %) With Post-baseline Potentially Clinically Important Changes in ECG (40 Weeks Treatment Duration); Subjects (N, %) With Post-baseline Potentially Clinically Important Changes in Vital Signs (40 Weeks Treatment Duration); Subjects (N, %) With Post-baseline Potentially Clinically Important Changes in Body Weight (40 Weeks Treatment Duration); Subjects (N, %) With Post-baseline Potentially Clinically Important Changes (40 Weeks Treatment Duration) 2022-08-19 | Completed. Key figures are not recorded here; the rationale explains the result. | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (3)
What this study did
What this study did
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (2)
What this study did
What this study did
Early phase / not applicable (1)
What this study did
Competitive landscape
This drug's own stage for Rett Syndrome: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Trofinetide: this drug | Approved | Peptide | — | Reliable signal | No reviewed efficacy summary in this indication | |
| Fenfluramine (Fintepla) | Phase 3 | Small molecule | Serotonin 5-HT2 receptors | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Trofinetide to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.